Rini Brian I, Flaherty Keith
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Urol Oncol. 2008 Sep-Oct;26(5):543-9. doi: 10.1016/j.urolonc.2008.03.012.
Vascular endothelial growth factor (VEGF) pathway activation leads to the angiogenic phenotype of renal cell carcinoma (RCC). Several different strategies targeting various aspects of this pathway have emerged as standard therapy in metastatic RCC. Bevacizumab, a VEGF ligand-binding antibody, sunitinib and sorafenib, small molecule inhibitors of the VEGF receptor, as well as temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) have all shown substantial clinical activity in metastatic RCC. Several relevant clinical aspects have also emerged with use of these agents such as defining resistance, measurement of response, and combination therapy.
血管内皮生长因子（VEGF）信号通路的激活导致肾细胞癌（RCC）的血管生成表型。针对该信号通路不同方面的几种不同策略已成为转移性RCC的标准治疗方法。贝伐单抗，一种VEGF配体结合抗体，舒尼替尼和索拉非尼，VEGF受体的小分子抑制剂，以及替西罗莫司，一种哺乳动物雷帕霉素靶蛋白（mTOR）的抑制剂，在转移性RCC中均显示出显著的临床活性。使用这些药物还出现了几个相关的临床问题，如定义耐药性、反应测量和联合治疗。
